| 5.46 Data as of May 17 |  +0.05 / +0.92%Today’s Change | 2.30 Today|||52-Week Range 6.85 | +30.00% Year-to-Date |
| Previous close | 5.41 |
| Today’s open | 5.44 |
| Day’s range | 5.35 - 5.48 |
| Volume | 216,330 |
| Average volume (3 months) | 338,559 |
| Market cap | $281.8M |
| Dividend yield | -- |
| Earnings growth (last year) | -111.63% |
| Earnings growth (this year) | +10.57% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -24.92% |
| P/E ratio | NM |
| Price/Sales | 53.87 |
| Price/Book | 23.55 |
| Today’s change | Today’s % change | |
|---|---|---|
| RGENRepligen Corp | -0.03 | -0.34% |
| NAVBNavidea Biopharmaceu... | +0.04 | +1.70% |
| CNDOCoronado Biosciences... | -0.17 | -1.69% |
| SCLNSciClone Pharmaceuti... | -0.14 | -2.82% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $3.8M |
| Annual profit (last year) | -$44.0M |
| Net profit margin | -1,170.78% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Daniel N. Swisher, Jr., MBA |
CFO, Secretary & EVP-Corporate Development Eric H. Bjerkholt, MBA |
Corporate headquarters South San Francisco, California |
.
